Validation of HC250 and HC240 Series.

NCT ID: NCT00739011

Last Updated: 2008-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to determine the effectiveness of two different CPAP devices. One a standard CPAP which has the ability to store comprehensive compliance and efficacy data and the second a auto adjusting CPAP which uses the energy spectrum analysis of flow signals to automatically adjust CPAP pressure and improve sleep variables.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients with suspected obstructive sleep apnea presenting at the Auckland Hospital Sleep Laboratory and referred for either a split-night or full night diagnostic study, will be offered participation in the study and will be recruited. From these patients, a total of 20 patients that are diagnosed with clinical obstructive sleep apnea syndrome, based on diagnostic polysomnography, will undergo titration with the HC254 Auto CPAP. An additional 20 patients will undergo titration with the HC244 CPAP.

The sleep physiologist evaluating the patient clinically will approach patients for participation in this study during their sleep laboratory visit. Consenting patients will undergo either an initial full night diagnostic polysomnography or a split night study as determined by the physician based on clinical requirements. Patients diagnosed with obstructive sleep apnea (AHI \> 15/hr) during this diagnostic component will then undergo one of the following:

* Treatment with the HC254 Auto CPAP during the second half of the study.
* Treatment with the HC244 CPAP during the second half of the study.

The sleep physiologist will then determine final CPAP prescriptions for all patients based on the patient's response to CPAP therapy.

5 subjects who have completed the HC254 arm of the study will be brought back to the sleep lab for an additional PSG or partial PSG while on CPAP pressure set to 90th percentile pressure determined on the diagnostic night.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea (OSA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

SleepStyle 254/244 CPAP series CPAP humidifier

Intervention Type DEVICE

Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SleepStyle 254/244 CPAP series CPAP humidifier

Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AHI \> 15 on the diagnostic night or portion of the split night study.
* ≥18yrs of age

Exclusion Criteria

* Significant Central Apnea
* CHF
* Co-existing obesity related hypoventilation
* Inability to give informed consent
* Patient intolerance to CPAP
* Anatomical or physiological conditions making CPAP therapy inappropriate.
* Less than 3 hours in the titration period
* Under Land Transport New Zealand (LTNZ) investigation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fisher and Paykel Healthcare

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fisher and Paykel Healthcare

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jessica Hayward, MSc

Role: PRINCIPAL_INVESTIGATOR

Fisher and Paykel Healthcare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Auckland Hospital Sleep laboratory

Auckland, , New Zealand

Site Status

Auckland Physiology Sleep Lab

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

New Zealand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FPHC240/250Val

Identifier Type: -

Identifier Source: org_study_id